Granted Patent
B2
US 12,576,081 · App. 16/938,642 · Granted Mar 17, 2026
Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions
Inventors:
James L. Yeager (Lake Forest, IL); David J. Goldberg (Philadelphia, PA); Stephen M. Paridon (Strafford, PA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have undergone Fontan surgery and who have Fontan circulation (Fontan patient), to improve exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in the SVHD patients, including the Fontan patients, using udenafil compositions. In one exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan, to improve the ventricular performance of the SVHD patient's, including the Fontan patient's, single functioning ventricle. In another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, MPI. In still another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, cardiac output. In yet another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, who is about 6 years of age or older, to improve at least one or more or all of the following in the SVHD patient, including the Fontan patient: (a) ventricular performance of the SVHD patient's, including a Fontan patient's, single functioning ventricle as measured by MPI; (b) exercise capacity as measured by oxygen consumption at anaerobic threshold (VAT); (c) exercise capacity as measured by oxygen consumption at maximal effort or max VO 2 ; (d) work rate at VAT; (e) VE/VCO 2 at VAT; diastolic blood pressure at rest; and (g) oxygen saturation (%) at rest.
Claims (13)
1 . A method of improving a Fontan patient's exercise capacity, comprising: administering 87.5 mg of udenafil or a pharmaceutically acceptable salt thereof twice daily to the Fontan patient, wherein said method increases oxygen consumption at the ventilatory anaerobic threshold (VAT).
2 . The method according to claim 1 , wherein said method improves ventilatory equivalents of carbon dioxide (VE/VCO 2 ) at VAT.
3 . The method according to claim 1 , wherein said method increases work rate at VAT.
4 . The method according to claim 2 , wherein said method increases work rate at VAT.
5 . The method according to claim 1 , wherein said method increases oxygen consumption at peak exercise capacity.
6 . The method according to claim 5 , wherein said method improves ventilatory equivalents of carbon dioxide (VE/VCO 2 ) at VAT.
7 . The method according to claim 5 , wherein said method increases work rate at VAT.
8 . The method according to claim 6 , wherein said method increases work rate at VAT.
9 . The method according to claim 1 , wherein said method results in minimal or no side effects caused to the Fontan patient.
10 . The method according to claim 1 , wherein the patient is an adolescent.
11 . The method according to claim 1 , wherein the patient is between about 12 and about 19 years old.
12 . The method according to claim 1 , wherein the patient is between about 12 and about 18 years old.
13 . The method according to claim 1 , wherein the patient is an adult.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 17, 2024
From: YEAGER, JAMES L.
To: MEZZION PHARMA CO., LTD.
Reel/Frame 068608/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 24, 2024
From: YEAGER, JAMES L.
To: MEZZION PHARMA CO., LTD.
Reel/Frame 067203/0973 →
CONFIRMATORY LICENSE
Recorded Oct 13, 2023
From: CHILDREN'S HOSP OF PHILADELPHIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065238/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 29, 2020
From: GOLDBERG, DAVID; PARIDON, STEPHEN
To: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Reel/Frame 054208/0932 →
Continuity (4)
Provisional Application
63023070
· May 11, 2020
Provisional Application
62936497
· Nov 16, 2019
Provisional Application
62905350
· Sep 24, 2019
References Cited (278)
US 20050272741A1
· Rychik et al.
· 2005
[cited by applicant]
US 20110250279A1
· Yoo et al.
· 2011
[cited by applicant]
US 20110306762A1
· Lee et al.
· 2011
[cited by applicant]
US 20190030037A1
· Yeager et al.
· 2019
[cited by applicant]
US 20190030038A1
· Yeager et al.
· 2019
[cited by applicant]
US 20230095034A1
· Yeager et al.
· 2023
[cited by applicant]
CA 3128705A1
· 2016
[cited by examiner]
EC SP088311A
· 2008
[cited by applicant]
EC SP088441A
· 2008
[cited by applicant]
JP 2012197274A
· 2012
[cited by applicant]
JP 2013514995A
· 2013
[cited by applicant]
JP 2013523809A
· 2013
[cited by applicant]
JP 2010532319A
· 2017
[cited by applicant]
KR 100792126B1
· 2008
[cited by applicant]
KR 20070099363A
· 2008
[cited by applicant]
KR 1020130086771A1
· 2013
[cited by applicant]
KR 101383430A1
· 2014
[cited by applicant]
RU 2420289C1
· 2011
[cited by applicant]
WO WO2006132460A1
· 2006
[cited by applicant]
WO WO00027848A1
· 2008
[cited by applicant]
WO WO2014078459A1
· 2014
[cited by applicant]
Ghosh, Anaerobic Threshold: Its Concept and Role in Endurance Sport, Malaysian Journal of Medical Sciences, Jan. 2004, pp. 24-36 (Year: 2004).
[cited by examiner]
AHA names top heart disease and stroke research advances of 2019, American Heart Association, 2019, (5 pages).
[cited by applicant]
Albouaini K et al., Cardiopulmonary exercise testing and its application, Heart, 2007, 93(10):1285-1292.
[cited by applicant]
Amrhein V et al., Retire statistical significance, Nature, 2019, 567:305-307.
[cited by applicant]
Center for Drug Evaluation and Research, Application No. 203109Orig1s000, Summary Review, 2012 (19 pages).
[cited by applicant]
Choi et al., Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. A novel therapeutic option for portal hypertension. Arzneimittelforschung, 2009, 59(12):641-6.
[cited by applicant]
Ciliberti P et al., Modulation of pulmonary vascular resistance as a target for therapeutic interventions in fontan patients: focus on phosphodiesterase inhibitors, Future Cardiol, 2012, 8(2):271-284.
[cited by applicant]
Giardini A et al., Effect of sildenafil on haemodynamic response to exercise and exercise capacity in fontan patients, Eur Heart J, 2008, 29(13):1681-1687.
[cited by applicant]
Goldberg DJ et al., Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial, Circulation, 2011, 123(11):…
[cited by applicant]
Goldberg DJ et al., Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation, Am Heart J, 2018, 188:42-52.
[cited by applicant]
Goldberg DJ et al., Results of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial, Circulation, 2020 (34 pages).
[cited by applicant]
Goldberg DJ et al., Sildenafil improves ventricular performance in children and young adults after the fontan operation, Circulation, 2009, 120:S603.
[cited by applicant]
Kim A, et al. Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment, Br J Clin Pharmacol, 2016, 82(2): 389-398.
[cited by applicant]
Kim HL et al., Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy, Hypertens Res, 2015, 38(9):597-604.
[cited by applicant]
Kim K et al., PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic function and exercise capacity in patients with chronic systolic heart failure: a 12-week randomized, double-blind, placebo-contr…
[cited by applicant]
Kim KH et al., Udenafil improves exercise capacity and left ventricular remodeling in patients with systolic heart failure, JACC, 2014, 63(12): A535.
[cited by applicant]
Lichtinghagen R et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values, J Hepatol, 2013, 59(2):236-42.
[cited by applicant]
Mullard A, Parsing clinical success rate,
[cited by applicant]
Paridon SM et al., A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation, JACC, 2008, 52(2):99-107.
[cited by applicant]
Park JS et al., Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study, COPD, 2012, 9(5):499-504.
[cited by applicant]
Shabanian R et al., Sildenafil and ventriculo-arterial coupling in fontan-palliated patients: a noninvasive echocardiographic assessment, Pediatr Cardiol, 2013, 34:129-134.
[cited by applicant]
AHA names top heart disease and stroke research advances of 2019, American Heart Association, dated: Dec. 13, 2019, 5 pages.
[cited by applicant]
Akagi et al., “Influence of ventricular morphology on diastolic filling performance in double-inlet ventricle after the Fontan procedure”, J. Am. Coll. Cardiol., Dec. 1993, vol. 22, No. 7, pp. 1948-1952.
[cited by applicant]
Albouaini, K et al., “Cardiopulmonary exercise testing and its application”, Heart, vol. 93, No. 10, (2007), pp. 1285-1292.
[cited by applicant]
Amrhein et al., “Scientists rise up against statistical significance”, Nature, Mar. 2019, vol. 567, No. 7748, pp. 305-307.
[cited by applicant]
Andersen et al., “Sildenafil and diastolic dysfunction after acute myocardial infarction trial: rationale and design”, Clin. Cardiol., Apr. 2013, vol. 36, No. 4, pp. 85-98.
[cited by applicant]
Anderson et al., “Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study”, J. Am. Coll., Jul. 8, 2008, vol. 52, No. 2, pp. 85-98.
[cited by applicant]
Argiento et al., “Exercise stress echocardiography for the study of the pulmonary circulation”, Eur. Respir J., Jun. 2010, vol. 35, No. 6, pp. 1273-1278.
[cited by applicant]
Attina et al., “Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilation in hypertensive patients”, J. Hypertens, Mar. 2008, vol. 26, No. 3, pp. 501-507.
[cited by applicant]
Australian Examination Report mailed Feb. 21, 2018, for Australian Patent Application No. 201502271, 4 pages.
[cited by applicant]
Australian Notice of Acceptance for Patent Application No. 201502271 dated Feb. 19, 2019, 4 pages.
[cited by applicant]
Avitabile et al., “A multifaceted approach to the management of plastic bronchitis after cavopulmonary palliation”, Ann. Thorac. Surg., Aug. 2014, vol. 98, No. 2, pp. 634-640.
[cited by applicant]
Barst et al., “STARTS-2 Investigators. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naïve pediatric pulmonary arterial hypertension”, Circulation, May 13, 2014, vol. 129, No. 19, pp. 1914-1…
[cited by applicant]
Behling et al., “Effect of 5-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial”, J. Card. Fail., (Apr. 2008), vol. 14, …
[cited by applicant]
Bialkowski et al., [Successful chronic treatment with sildenafil in a patient with end-stage heart failure following Fontan procedure], Kardiol. Pol., (vol. 69, No. 3, (2011), pp. 302-304., Polish., [English Abstract].
[cited by applicant]
Binotto et al., “Altered endothelial function following the Fontan procedure”, Cardiol. Young, Feb. 2008, vol. 18, No. 1, pp. 70-74.
[cited by applicant]
Blum et al., “Treating heart failure with sildenafil”, Congest Heart Fail., Jul.-Aug. 2009, vol. 15, No. 4, pp. 181-185.
[cited by applicant]
Boolell et al., Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int'l. J. Impot. Res., vol. 8, No. 47, (1996), [Abstract].
[cited by applicant]
Canadian Office Action for Application No. 2,954,183, dated Apr. 27, 2018, 4 pages.
[cited by applicant]
Canadian Office Action for Application No. 2,954,183, dated Feb. 4, 2019, 3 pages.
[cited by applicant]
Canter et al., “Indications for heart transplantation in pediatric disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Council on Clinical Cardiology, …
[cited by applicant]
Center for Drug Evaluation and Research, Application No. 203109Orig1s000, Summary Review, dated: 2012, 19 pages.
[cited by applicant]
Cheung et al., “Serial assessment of left ventricular diastolic function after Fontan procedure”, Heart, Apr. 2000, vol. 83, No. 4, pp. 420-424.
[cited by applicant]
Chilean Office Action for Application No. 201700329 dated May 17, 2018, 8 pages. [Original].
[cited by applicant]
Chilean Office Action for Application No. 201700329 dated May 17, 2018, 8 pages. [English Translation].
[cited by applicant]
Chilean Office Action for Application No. 201700329 dated May 27, 2018, 10 pages. [Original].
[cited by applicant]
Chilean Office Action for Application No. 201700329 dated May 27, 2018, 8 pages. [English Translation].
[cited by applicant]
Chinese Office Action for Application No. 201580040518.0, dated Feb. 19, 2019, 15 pages. [English Translation].
[cited by applicant]
Chinese Office Action for Application No. 201580040518.0, dated Feb. 19, 2019, 10 pages. [Original].
[cited by applicant]
Chinese Office Action for Application No. 201580040518.0, dated Nov. 25, 2019, 15 pages. [English Translation].
[cited by applicant]
Chinese Office Action for Application No. 201580040518.0, dated Nov. 25, 2019, 3 pages. [Original].
[cited by applicant]
Chinese Office Action for Application No. 2024101406105, dated Jan. 4, 2025, 29 pages. [Original].
[cited by applicant]
Chinese Office Action for Application No. 2024101406105, dated Jan. 4, 2025, 5 pages. [English Translation].
[cited by applicant]
Choi et al., “Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. A novel therapeutic option for portal hypertension.”, Arzneimittelforschung, 2009, vol. 59 No. 12, pp. 641-646.
[cited by applicant]
Ciliberti, et al., “Modulation of pulmonary vascular resistance as a target for therapeutic intervention in Fontan patients: focus on phosphodiesterase inhibitors”, Future Cardiol., Mar. 2012, vol. 8, No. 2, pp. 271-284.
[cited by applicant]
Ciliberti, et al., “Impact of Oral Chronic Administration of Sildenafil in Children and Young Adults after the Fontan Operation”, Future Cardiol., Sep. 2011, vol. 7, No. 5, pp. 609-612.
[cited by applicant]
ClinicalTrials.gov—“Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients”, NCT01291069, Feb. 4, 2011, <https://clinicaltrials.gov/ct2/show/NCT01291069>.
[cited by applicant]
ClinicalTrials.gov—“Pharmacokinetics/Pharmacodynamic Study of Udenafli in Adolescents”, NCT02201342, Jul. 24, 2014, <https://clinicaltrials.gov/ct2/show/NCT02201342?term=udenafil+and+fontan@rank=2>.
[cited by applicant]
ClinicalTrials.gov—A Service of the U.S. National Institutes of Health, Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents, Jul. 21, 2016, 4 pages.
[cited by applicant]
ClinicalTrials.gov—A Service of the U.S. National Institutes of Health, Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL), Jul. 21, 2016, 4 pages.
[cited by applicant]
ClinicalTrials.gov—A Service of the U.S. National Institutes of Health, Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents, Apr. 10, 2015, 4 pages.
[cited by applicant]
ClinicalTrials.gov—A Service of the U.S. National Institutes of Health, Changes to NCT02201342, Apr. 26, 2015, 3 pages.
[cited by applicant]
ClinicalTrials.gov archive—View of NCT02201342 on Jul. 25, 2014, available at https://clinicaltrials.gov/ct2/history/NCT02201342/2014_07_25, accessed on Feb. 19, 2018.
[cited by applicant]
ClinicalTrials.gov archive—History of Changes for Study: NCT02201342 available at https://clinicaltrials.gov/ct2/keyates/NCT02201342?A=1&B=2&C=merged#StudyPageTop, accessed on Sep. 14, 2018.
[cited by applicant]
ClinicalTrials.gov—Key Record Dates, available at https://clinicaltrials.gov/ct2/history/NCT02201342, accessed on Sep. 14, 2018.
[cited by applicant]
Colombia Office Action for Application No. NC2017/0000271 [English Translation].
[cited by applicant]
Colombia Office Action for Application No. NC2017/0000271 [Original].
[cited by applicant]
Colombia Office Action for Application No. NC2017/0000271, dated Apr. 4, 2019, [English Translation].
[cited by applicant]
Colombia Office Action for Application No. NC2017/0000271, dated Apr. 4, 2019, [Original].
[cited by applicant]
Colombian Office Action mailed Mar. 5, 2018, for Colombian Patent Application No. NC2017/0000271, 4 pages. [Original].
[cited by applicant]
Colombian Office Action mailed Mar. 5, 2018, for Colombian Patent Application No. NC2017/0000271, 4 pages. [English Translation].
[cited by applicant]
Colombian Office Action for Application No. NC2017/0000271, dated Oct. 4, 2018, 6 pages. [Original].
[cited by applicant]
Colombian Office Action for Application No. NC2017/0000271, dated Oct. 4, 2018, 6 pages. [English Translation].
[cited by applicant]
Company Report, Mezzion (140410), (dated Apr. 23, 2013, available at http://cfile30.uf.tistory.com/attach/273A264E517619D80E3D0D, accessed on May 27, 2016).
[cited by applicant]
Deal et al., “Management of the failing Fontan Circulation”, Heart, Jul. 2012, vol. 98, No. 4, pp. 1098-1104.
[cited by applicant]
Diller et al., “Exercise intolerance in adult congenital heart disease; comparative severity, correlates, and prognostic implication”, Circulation, Aug. 9, 2005, vol. 112, No. 6, pp. 828-835.
[cited by applicant]
Diller et al., “Predictors of morbidity and mortality in contemporary Fontan patients; results from a multicenter study including cardiopulmonary exercise testing in 321 patients”, Eur. Heart. J., Dec. 2010, vol. 31, No…
[cited by applicant]
Dominican Republic Office Action for Application No. P2017-0014, dated Jan. 23, 2019, 3 pages. [Original].
[cited by applicant]
Dominican Republic Office Action for Application No. P2017-0014, dated Jan. 23, 2019, 6 pages. [English Translation].
[cited by applicant]
D'Udekem et al., “How good is a good Fontan? Quality of life and exercise capacity of Fontans without Arrhythmias”, Ann Thorac Surg., Dec. 2009, vol. 88, No. 6, pp. 1961-1969.
[cited by applicant]
Ecuador Opposition Notice for Patent Application No. IEPI 2017-15154 dated Nov. 30, 2018, 12 pages. [Original].
[cited by applicant]
Ecuador Opposition Notice for Patent Application No. IEPI 2017-15154 dated Nov. 30, 2018, 12 pages. [English Translation].
[cited by applicant]
Ellis, S., “Mezzion's PDE5 inhibitor enters U.S. trials for Fontan patients”, BioWorld, Jan. 22, 2014, <http:www.bioworld.com/content/mezzion%E2%80%99s-pde5-inhibitor-enters-us-trials-fontan-patients>.
[cited by applicant]
Eurasian Office Action for Application No. 201692518/28 May 4, 2018, 2 pages. [English Translation].
[cited by applicant]
Eurasian Office Action for Application No. 201692518/28 May 4, 2018, 2 pages. [Original].
[cited by applicant]
Eurasian Office Action and Search Report for Application No. 201692518 dated Jul. 20, 2017 [English Translation].
[cited by applicant]
Eurasian Office Action and Search Report for Application No. 201692518 dated Jul. 20, 2017 [Original].
[cited by applicant]
European Search Report mailed Jan. 4, 2018, for European Patent Application No. 15831606.7, filed Jun. 30, 2015, 12 pages.
[cited by applicant]
European Office Action for Patent Application No. 15831606.7, dated Apr. 26, 2019, 6 pages.
[cited by applicant]
European Office Action for Patent Application No. 20869034.7, dated Sep. 17, 2025, 6 pages.
[cited by applicant]
European Search Opinion for EP Application No. 23212824.9, dated May 24, 2024, 9 pages.
[cited by applicant]
“Evaluation of Fontan-Associated Liver Disease”, URL: https://clinicaltrials.gov/ct2/show/record/NCT03430583, date accessed: Sep. 25, 2024, 7 pages.
[cited by applicant]
Extended European Search Report for EP Application No. 23212824.9 dated May 24, 2024, 19 pages.
[cited by applicant]
Exhibit a-1 to Declaration of James L. Yeager and Won Geun Kim Under 37 CFR Section 1.130, dated Jul. 30, 2017 (referred to herein as “Declaration”): Email from ClinicalTrials.gov to James L. Yeager confirming receipt o…
[cited by applicant]
Exhibit b-1 to Declaration: Press release entitled “Mezzion Pharma Announces Collaboration with New England Research Institutes to Evaluate Udenafil in Adolescents with Single Ventricles Heart Defects” (Jan. 10, 2014).
[cited by applicant]
Exhibit b-2 to Declaration: Email from PR Newswire to James L. Yeager, dated Jan. 9, 2014.
[cited by applicant]
Exhibit b-3 to Declaration: Email from PR Newswire to James L. Yeager, dated Jan. 9, 2014.
[cited by applicant]
Exhibit c-1 to Declaration: Email from Youn-Taek Song (IR Team/Manager for Mezzion Pharma) to Minha Choi of Korean Investment regarding Exhibit c-2, the “Company Report, Mezzion (140410)” (Aug. 13, 2013).
[cited by applicant]
Exhibit c-2 to Declaration: Mezzion report entitled “Company Report, Mezzion (140410)” (Aug. 13, 2023).
[cited by applicant]
Exhibit c-3 to Declaration: Mezzion report entitled “Mezzion Inventor Relations” (Jul. 2013). [Original].
[cited by applicant]
Exhibit c-3 to Declaration: Mezzion report entitled “Mezzion Inventor Relations” (Jul. 2013) [English Translation].
[cited by applicant]
Exhibit c-4 to Declaration: Mezzion report entitled “Mezzion Investor Relations” (Jun. 2014).
[cited by applicant]
Exhibit h-1 to Declaration: Email from PR Newswire confirming receipt of the content of Exhibit h-2 submitted by James L. Yeager, on behalf of Mezzion (Oct. 9, 2014).
[cited by applicant]
Exhibit i-1 to Declaration: Email from Youn-Taek Song (IR Team/Manager for Mezzion Pharma) to Sae-Bom Lee of Maeil Business Newspaper. Exhibit i-1 was submitted with four attachments, i.e., (1) Exhibit i-2, Jan. 9, 2014…
[cited by applicant]
Exhibit i-2 to Declaration: Press release entitled “Zydena in the United States acquired the patent applications for the enlarged Benign prostatic hyperplasia treatment effect”, (Jan. 9, 2014).
[cited by applicant]
Exhibit i-3 to Declaration: “Dong-A Pharmatech IR report”, (Jan. 2012).
[cited by applicant]
Exhibit i-3 to Declaration: “Dong-A Pharmatech IR report”, (Jan. 2012). [English Translation].
[cited by applicant]
Exhibit i-4 to Declaration: Press release entitled “Zydena, Approved by the Ethics Committee in Mexico”, (Jul. 23, 2012).
[cited by applicant]
Exhibit i-5 to Declaration: Press release entitled “Dong-A Pharmtech, Russian Market Second development export after 2007”, (May 16, 2012).
[cited by applicant]
Exhibit j-1 to Declaration: Email from Youn-Taek Song (IR Team/Manager for Mezzion Pharma) to reporter Dong In Lee of Maeil Business Newspaper. Attached to Exhibit j-1 is Exhibit j-2, a press release (Mar. 31, 2015).
[cited by applicant]
Exhibit j-2 to Declaration: Press release entitled “Mezzion, return exclusive rights (develop and marketing) to erectile dysfunction and Benign prostatic hyperplasia in the Americas” (Mar. 31, 2015).
[cited by applicant]
Exhibit k-1 to Declaration: Email from Youn-Taek Song (IR Team / Manager for Mezzion Pharma) to reporter YooJin Jo of Asia Business Daily. Attached to Exhibit k-1 are Exhibits k-2, K-3 and K-4 (Jun. 20, 2015).
[cited by applicant]
Exhibit k-2 to Declaration: Press release entitled Mezzion, completes to ½ Clinical Trials of Udenafil in Fontan patients (Mar. 16, 2015).
[cited by applicant]
Exhibit k-3 to Declaration: Press release entitled “Mezzion Pharma Announces Collaboration with New England Research Institutes to Evaluate Udenafil in Adolescents with Fontan Surgery”, (Jan. 10, 2014).
[cited by applicant]
Exhibit k-4 to Declaration: Press release entitled “Mezzion, submit uses patent application for Fontan Operation”, (Jun. 29, 2015).
[cited by applicant]
Exhibit I to Declaration: Correspondence to reporter Hyoung-Su Park of Edaily by Youn-Tack Song (IR Team/Manager for Mezzion Pharma) on behalf of Mezzion by e-mail on Mar. 26, 2014 for the purpose of an analyst report […
[cited by applicant]
Exhibit m to Declaration: Correspondence regarding company presentation submitted to analysts by Youn-Tek Song (IR Team/Manager for Mezzion Pharma) on behalf of Mezzion by e-mail on Mar. 26, 2014 for the purpose of an A…
[cited by applicant]
Exhibit A to Jun. 22, 2018 Response: Karkoswsky, Abraham. “Summary Review: NDA 203109 Sildenafil Citrated Powder for Reconstitution.” Drugs@FDA: FDA Approved Drug Products, US Food & Drug Administration, Reference ID: 3…
[cited by applicant]
Exhibit B to Jun. 22, 2018 Response: “Labeling-Package Insert; NDA 203109 Sildenafil Citrated Powder for Reconstitution.” Drugs@FDA: FDA Approved Drug Products, US Food & Drug Administration, Reference ID: 3471998. Mar.…
[cited by applicant]
Exhibit C to Jun. 22, 2018 Response: Sung, Hyun Hwan, and Sung Won Lee.“Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction”, Korean Journal of Urology, vol. 53, No. 6, 2012, pp. 377-385, d…
[cited by applicant]
Exhibit D to Jun. 22, 2018 Response: Anderson, Page A.W., et al., “The Fontan Patient: Inconsistencies in Medication Therapy Across Seven Pediatric Heart Networks Centers.” Pediatric Cardiology, vol. 31, No. 8, 2010, pp…
[cited by applicant]
Fernandes et al., “Serial cardiopulmonary exercise testing in patients with previous Fontan surgery”, Pediatr. Cardiol., Feb. 2010, vol. 31, No. 2, pp. 175-180.
[cited by applicant]
Fontan et al., “Surgical repair of tricuspid atresia”, Thorax, May 1971, vol. 26, No. 3, pp. 240-248.
[cited by applicant]
“Fontan Circulation: success or failure?”, Congenital Heart Defect Research Blog, Mar. 13, 2013, <http:bendantzer.wordpress.com/2013/03/13/fontan-circulation-success-or-failure/>.
[cited by applicant]
Frommelt et al., “Doppler assessment of pulmonary artery flow patterns and ventricular function after the Fontan operation”, A. J. Cardiol., Nov. 1991, vol. 68, No. 1, pp. 1211-1215.
[cited by applicant]
Galie et al., “Sildenafil citrate therapy for pulmonary arterial hypertension”, N. Engl. J. Med., Nov. 17, 2005, vol. 353, No. 20, pp. 2148-2157.
[cited by applicant]
Galie et al., “Tadalafil therapy for pulmonary arterial hypertension”, Circulation, Jun. 9, 2009, vol. 119, No. 22, pp. 2894-2903.
[cited by applicant]
Gewilling, M. et al., “Failure of the Fontan Circulation”, Heart Failure Clinics, vol. 10, No. 1, 2014, pp. 105-116. doi:10.1016/j.hfc.2013.09.010.
[cited by applicant]
Gewilling et al., “The Fontan circulation; who controls cardiac output?”, Interact. Cardiovasc. Thorac Surg., Mar. 2010, vol. 10, No. 3, pp. 428-433.
[cited by applicant]
Gersony, W. M., “Fontan Operation After 3 Decades, What We Have Learned”, Circulation, vol. 117, (2008), pp. 13-15.
[cited by applicant]
Giardini, A. et al., “Effect of sildenafil on haelmodynamic response to exercise and exercise capacity in Fontan patients”, Eur. Hearts J., vol. 29, No. 13, Jul. 2008, pp. 1681-1687.
[cited by applicant]
Giardini, A. et al., “Usefulness of Cardiopulmonary Exercise to predict long-term prognosis in adults with repaired tetralogy of Fallot”, Am J. Cardiology, (May 15, 2007, e-published Apr. 5, 2007), vol. 99, No. 10, pp. …
[cited by applicant]
Giardini et al., “Natural history of exercise capacity after the Fontan operation; a longitudinal study”, Ann. Thorac Surg., Mar. 2008, vol. 85, No. 3, pp. 818-821.
[cited by applicant]
Giordano, et al., “First experience with sildenafil after Fontan operation; short-term outcomes”, J. Cardiovasc. Med., (Hagerstown), vol. 16, No. 8, Aug. 2015, pp. 552-555.
[cited by applicant]
Goldberg et al., “Fontan Circulation, The Search for Targeted Therapy”, Circulation, vol. 130, (2014), pp. 1999-2001.
[cited by applicant]
Goldberg et al., “Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation”, Pediatr. Cardiol., vol. 33, No. 5, Jun. 2012, pp. 689-696.
[cited by applicant]
Goldberg, D. J. et al. “Impact of Oral Sildenafil on Exercised Performance in Children and Young Adults After the Fontan Operation—A Randomized, Double-Blind, Placebo- Controlled, Crossover Trial”, Circulation, vol. 123…
[cited by applicant]
Goldberg et al., “Abstract 2161: Sildenafil Improves Ventricular Performance in Children and Young Adults After the Fontan Operation”, Circulation, (2009), vol. 120, S603.
[cited by applicant]
Goldberg et al., “Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation”, Am. Heart J., Jun. 2017, vol. 188, pp. 42-52.
[cited by applicant]
Goldberg et al., Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial, Am. Heart J., Apr. 2018, vol. 201, pp. 1-8.
[cited by applicant]
Goldberg et al., Results of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial, Circulation, 2020, 34 pages.
[cited by applicant]
Goldberg, et al., “Exercise Capacity and Predictors of Performance After Fontan: Results from the Pediatric Heart Network Fontan 3 Study”, Pediatric Cardiology, vol. 42, (2021), pp. 158-168.
[cited by applicant]
Goldstein et al., “Relation of systemic venous return, pulmonary vascular resistance, and diastolic dysfunction to exercise capacity in patients with single ventricle receiving fontan palliation”, Am. J. Cardiol., Apr. …
[cited by applicant]
Goldstein et al., “Usefulness of peripheral vascular function to predict functional health status in patients with Fontan circulation”, Am. J. Cardiol., Aug. 1, 2011, vol. 108, No. 3, pp. 428-434.
[cited by applicant]
Guazzi et al., “PDE5 Inhibition with sildenafil improves ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized…
[cited by applicant]
Guazzi et al., “Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study”, Circulation, Jul. 12, 2011, vol. 124, No. 2, pp. 164-174.
[cited by applicant]
Gu Kang et al., “Udenafil: efficancy and tolerability in the management of erectile dysfunction”, Ther. Adv. Urol., vol. 5, No. 2, (2013), pp. 101-110.
[cited by applicant]
Haseyama et al., “Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome”, J. Thorac. Cardiovasc. Surg., Nov. 2006, vol…
[cited by applicant]
Hebert, A. et al., “Bosentan Improves Exercise Capacity in Adolescents and Adults After Fontan Operation: The TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Radomized, Placebo-Controlled, Dou…
[cited by applicant]
Highlights of Prescribing Information for REVATIO, Pfizer, 2014, 30 pages.
[cited by applicant]
Hosein, et al., “Factors influencing early and late outcome following the Fontan procedure in the current era. The ‘Two Commandants’?”, Eur. J. Cardiothorac. Surg., Mar. 2007, vol. 31, No. 3, pp. 344-353.
[cited by applicant]
Huddleston et al., “Sildenafil for the treatment of pulmonary hypertension in pediatric patients”, Pediatr. Cardiol., Oct. 2009, vol. 30, No. 7, pp. 871-872.
[cited by applicant]
Humpl et al., “Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study”, Circulation, Jun. 21, 2005, vol. 111, No.…
[cited by applicant]
Inai et al., “Skeletal muscle hemodynamics and endothelial function in patients after Fontan operation”, A. J. Cardiol., Mar. 2004, vol. 93, No. 6, pp. 792-797.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/040227, dated Feb. 13, 2024, 6 pages.
[cited by applicant]
Japanese Notification of Reasons for Refusal mailed Mar. 6, 2018, for Japanese Patent Application No. 2017-504434, 4 pages. [Original].
[cited by applicant]
Japanese Notification of Reasons for Refusal mailed Mar. 6, 2018, for Japanese Patent Application No. 2017-504434, 4 pages. [English Translation].
[cited by applicant]
Japanese Decision of Final Refusal for Application No. 2017-504434, dated Oct. 2, 2018, 14 pages. [Original].
[cited by applicant]
Japanese Decision of Final Refusal for Application No. 2017-504434, dated Oct. 2, 2018, 14 pages. [English Translation].
[cited by applicant]
Japanese Notice of Reasons for Refusal for Japanese Patent Application No. 2024-214477, dated Mar. 25, 2025, 5 pages. [Original].
[cited by applicant]
Japanese Notice of Reasons for Refusal for Japanese Patent Application No. 2024-214477, dated Mar. 25, 2025, 5 pages. [English translation].
[cited by applicant]
Jenkins et al., “Decreased exercise performance with age in children with hypoplastic left heart syndrome”, J. Pediatr., Apr. 2008, vol. 152, No. 4, pp. 507-512.
[cited by applicant]
Jin et al., “Impaired vascular function in patients with Fontan circulation”, Int. J. Cardiol., Aug. 21, 2007, vol. 120, No. 2, pp. 221-226.
[cited by applicant]
Kaneko et al., “Single right ventricles have impaired systolic and diastolic function compared to those of left ventricular morphology”, J. Am. Soc. Echocardiogr., Nov. 2012, vol. 25, No. 11, pp. 1222-1230.
[cited by applicant]
Keteyian et al., “Reproducibility of peak oxygen uptake and other cardiopulmonary exercise parameters: implications for clinical trials and clinical practice”, Chest, Oct. 2010, vol. 138, No. 4, pp. 950-955.
[cited by applicant]
Kim et al., “ULTIMATE-SHF trial (Udenafil Therapy to Improve symptomatology, exercise Tolerance and hemodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, dou…
[cited by applicant]
Kim et al., “DA-8159: Erectrogenic. Drugs of the Future”, (2005), vol. 30, No. 7, pp. 678-682.
[cited by applicant]
Kim, K. H. et al., “Udenafil Improves Exercise Capacity and Left Ventricular Remodeling in Patients with Systolic Heart Failure”, J. American College of Cardiology, Apr. 1, 2014, vol. 63, Issue 12, 1 page.
[cited by applicant]
Kim, K. H. et al., “Therapeutic Effects of Udenafil on Pressure-Overload Cardiac Hypertrophy”, Hypertens Res, (Sep. 2015, e-published Apr. 2, 2015), vol. 38, Issue 9, pp. 597-604.
[cited by applicant]
Kim, K. et al., “PDE 5 Inhibition with Udenafil Improves Left Ventricular Systolic/Diastolic Function and Exercise Capacity in Patients with Chronic Systolic Heart Failure: A 12-Week, Randomized, Double-Blind, Placebo-C…
[cited by applicant]
Kim et al., “Mezzion Pharma Announces Collaboration with New England Research Institutes to Evaluate Udenafil Adolescents with Single Ventricle Heart Defects”, Jan. 10, 2014, 2 pages.
[cited by applicant]
Kim et al., “Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects”, Br. J. Clin. Pharmacol., Jun. 2008, vol. 65, No. 6, pp. 848-854.
[cited by applicant]
Kim et al. “Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment”, Br J Clin Pharmacol, 2016, vol. 82, No. 2, pp. 389-398.
[cited by applicant]
Korean Office Action for Application No. 10-2017-7006695, dated Sep. 18, 2018, 3 pages. [Original].
[cited by applicant]
Korean Office Action for Application No. 10-2017-7006695, dated Sep. 18, 2018, 3 pages. [English Translation].
[cited by applicant]
Kouvelas, D. et al., “PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile”, Current Pharmaceutical Design, vol. 15, No. 30, (2009), pp. 3464-3475. doi: 10.2174/138161209789206971.
[cited by applicant]
Kruger et al., “Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs”, Circ. Res. Jan. 2, 2009, vol. 104, No. 1, pp. 87-94.
[cited by applicant]
La Gerche et al., “What Limits Cardiac Performance during Exercise in Normal Subjects and in Healthy Fontan Patients?”, Int. J. Pediatr., 2010.
[cited by applicant]
Lichtinghagen et al. “The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values”, J Hepatol, 2013, vol. 59, No. 2, pp. 236-242.
[cited by applicant]
Machine translation of “Company Report, Mezzion (140410)”, (dated Apr. 23, 2013, available at http://cfile30uf.tistory.com/attach/273A264E517619D80E3D0D, accessed on May 27, 2016).
[cited by applicant]
Mahle et al., “Endothelial Function following the Fontan operation”, Am. J. Cardiol., May 15, 2003, vol. 91, No. 10, pp. 1286-1288.
[cited by applicant]
Manlhiot et al., “Functional Health status of adolescents after the Fontan procedure—comparison with their siblings”, Can. J. Cardiol., Sep. 2009, vol. 25, No. 9, e294-300.
[cited by applicant]
Martin et al., “The Challenge of Patient Adherence”, Ther. Clin. Risk Manag., vol. 1, No. 3, (2005), pp. 189-199.
[cited by applicant]
Mccrindle et al., “Laboratory measures of exercise capacity and ventricular characteristics and function are weakly associated with functional health status after Fontan procedure”, Circulation, Jan. 5, 2010, vol. 121, …
[cited by applicant]
Mccrindle et al., “Relationship of patient and medical characteristics to health status in children and adolescents after the Fontan procedure”, Circulation, Feb. 28, 2006, vol. 113, No. 8, pp. 1123-1129.
[cited by applicant]
Meadows et al., “Fontan Fenestration Closure Has No Acute Effect on Exercise Capacity but Improves Ventilatory Response to Exercise”, J. Am. Coll. Cardiol., 2008, vol. 52, No. 2, pp. 108-113.
[cited by applicant]
Menon et al., “Single-Ventricle Cardiology: Palliation, Care and Resource Utilization”, Circulation, vol. 128, A1064, (2013), 2 pages. [Abstract].
[cited by applicant]
Menon, S.C. et al., “Effect of Tadalafil on Exercise Parameters in Young Fontan Patients”, Circulation, vol. 128: A16024 (2013), Abstract.
[cited by applicant]
Mezzion, “Global C&D business to post tangible results”, Aug. 13, 2013.
[cited by applicant]
“Mezzion Pharma Initiates Clinical Development Program to Evaluate Udenafil in Adolescents with Single Ventricle Heart Defects”, MedIndia. Jul. 23, 2024, <http://www.,medindia.net/health-press-release/Mezzion-Pharma-Ini…
[cited by applicant]
“Mezzion Pharma Initiates Clinical Development Program to Evaluate Udenafil in Adolescents with Single Ventricle Heart Defects”, Jul. 23, 2024, <http://www.prnewswire.com/news-releases/mezzion-pharma-lnitiates-clinical-…
[cited by applicant]
“Mezzion Pharma Announces Collaboration With New England Research Institutes to Evaluate Udenafil in Adolescents With Single Ventricle Heart Defects”, PR Newswire, Jan. 10, 2014, <http://www.prnewswire.com/news-releases…
[cited by applicant]
Morchi et al., “Sildenafil Increases Systemic Saturation and Reduces Pulmonary Artery Pressure in Patients with Failing Fontan Physiology”, Congenit. Heart Dis., vol. 4, No. 2, Apr. 2009, pp. 107-111.
[cited by applicant]
Mori, H et al., “Sildenafil Reduces Pulmonary Vascular Resistance in Patients with Single Ventricular Physiology”, (Nov. 26, 2013), Circulation, vol. 128, (Suppl. 22): A16117.
[cited by applicant]
Moroccan Office Action for Application No. 40095 dated Aug. 9, 2017 [English Translation].
[cited by applicant]
Moroccan Office Action for Application No. 40095 dated Aug. 9, 2017 [Original].
[cited by applicant]
Mourani et al., “Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease”, J. Pediatr., Mar. 2009, vol. 154, No. 3, e379-384. e2.
[cited by applicant]
Nagayama et al., “Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload”, J. Am.…
[cited by applicant]
Navaratnam et al., “Exercise-Induced Systemic Venous Hypertension in the Fontan Circulation”, Am J Cardiol., 2016, vol. 117, No. 10, 1667-1671.
[cited by applicant]
[cited by applicant]
New Zealand Further Examination Report for Application No. 727653 dated Aug. 10, 2018, 3 pages.
[cited by applicant]
New Zealand Further Examination Report for Application No. 727653 dated Apr. 24, 2018, 7 pages.
[cited by applicant]
New Zealand Office Action for Application No. 727653 dated Aug. 24, 2017, 7 pages.
[cited by applicant]
Ono et al., “Clinical outcome of patients 20 years after Fontan operation—effect of fenestration on late morbidity”, Eur. J. Cardiothorac Surg., Dec. 2006, vol. 30, No. 6, pp. 923-929.
[cited by applicant]
Panamanian Office Action for Application No. 91474 dated Apr. 20, 2017. [English Translation].
[cited by applicant]
Panamanian Office Action for Application No. 91474 dated Apr. 20, 2017. [Original].
[cited by applicant]
Panamanian Office Action for Application No. 91474 dated Sep. 18, 2018, 6 pages [English Translation].
[cited by applicant]
Panamanian Office Action for Application No. 91474 dated Sep. 18, 2018, 5 pages [Original].
[cited by applicant]
Paridon et al., “A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation”, J. Am. Coll. Cardiol., Jul. 8, 2008, vol. 52, No. 2, pp. 99-107.
[cited by applicant]
Park, J.S. et al., Udenafil Improves Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease: A Prospective Study, COPD: Journal of Chronic Obstructive Pulmonary Disease: 9.5, 499-504, (2012).
[cited by applicant]
Pundi et al., “40-year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients”, J. Am. Coll. Cardiol., Oct. 13, 2015, vol. 66, No. 15, pp. 1700-1710.
[cited by applicant]
Reinhardt et al., “Sildenafil in the management of the failing Fontan circulation”, Cardiol. Younq, Oct. 2010, vol. 20, No. 5, pp. 522-525.
[cited by applicant]
Rhodes, J. et al., “Effect of Inhaled Lloprost on the Exercise function of Fontan Patients: A Demonstration of Concept”, International Journal of Cardiology, vol. 168, No. 3, (2013), pp. 2435-2440. doi:10.1016/j.ijcard.…
[cited by applicant]
Rhodes et al., “Non-Geometric echocardiographic indices of ventricular function in patients with a Fontan circulation”, J. Am. Soc. Echocardiogr., Nov. 2011, vol. 24, No. 11, pp. 1213-1219.
[cited by applicant]
Rogers, L. S. et al., “18 Years of the Fontan Operation at a Single Institution, Journal of the American College of Cardiology”, vol. 60, No. 11, (2012), pp. 1018-1025, doi: 10.1016/j.jacc.2012.05.010.
[cited by applicant]
Rychik, J. et al., “Relentless Effects of the Fontan Paradox”, Seminars in Thoracic and Cardiovascular Surgery, vol. 19, No. 1, (2016), pp. 37-43.
[cited by applicant]
Rychik, J. et al., “Forty Years of the Fontan Operation: A Failed Strategy”, Pediatric Cardiact Surgery Annual, (2010), pp. 96-100.
[cited by applicant]
Sabri et al., “Effect of Tadalafil Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation”, Pediatr. Cardiol., vol. 37, (2016), pp. 55-61.
[cited by applicant]
Sabri et al., “Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension”, Pediatr. Cardiol., vol. 35, No. 4, (2014), pp. 699-704, [Abstr…
[cited by applicant]
Sanghavi et al., “Determinants of exercise function following univentricular versus biventricular repair for; pulmonary atresia/intact ventricular septum”, Am. J. Cardiol., Jun. 1, 2006, vol. 97, No. 11, pp. 1638-1643.
[cited by applicant]
Sano et al., “Assessment of ventricular contractile state and function in patients with univentricular heart”, Circulation, Jun. 1989, vol. 79, No. 6, pp. 1247-1256.
[cited by applicant]
Santos et al., “Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension”, Eur. J. Clin. Pharmacol., Feb. 2014, vol. 70, No. 2, pp. 147-154.
[cited by applicant]
Saudi Arabia Examination Report for Application No. 517380879, dated Jan. 2, 2019, 2 pages. [Original].
[cited by applicant]
Saudi Arabia Examination Report for Application No. 517380879, dated Jan. 2, 2019, 2 pages. [English Translation].
[cited by applicant]
Schilling et al., “The Fontan epidemic: Population projections from the Australia and New Zealand Fontan Registry”, Int. J. Cardiol., Sep. 15, 2016, vol. 219, pp. 14-19.
[cited by applicant]
Schuuring, M. J. et al., “Impact of Bosentan on Exercise capacity in Adults after the Fontan Procedure: a randomized controlled trial”, European Journal of Heart Failure, vol. 15, No. 6, (2013), pp. 690-698, doi:10.1093…
[cited by applicant]
Shabanian, R. et al., “Sildenafil and ventriculoarterial coupling in Fontan-palliated patients: a noninasive echocardiography assessment”, Pedatr. Cardiol, vol. 34, No. 1, (Jan. 2013, e-published Aug. 5, 2012), pp. 129-…
[cited by applicant]
Shon et al., “The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenalfil, and udenafil, is differently influenced by the CYP3A5 genotype”, Pharmacogenetics and Genomics, vol. 21, No. 12, (2011…
[cited by applicant]
Singapore Search Report and Written Opinion for Application No. 11201700060W dated Feb. 26, 2018, 9 pages.
[cited by applicant]
Snarr et al., “Pulmonary vasodilator therapy in the failing Fontan circulation: rationale and efficacy”, Cardiol. Young, Dec. 2015, vol. 25, No. 8, pp. 1489-1492.
[cited by applicant]
Stickland et al., “Does fitness level modulate the cardiovascular hemodynamic response to exercise?”, J. Appl. Physiol., Jun. 2006, vol. 100, No. 6, pp. 1895-1901.
[cited by applicant]
Taiwanese Office Action for Application No. 104121758, dated Apr. 8, 2019, 5 pages. [Original].
[cited by applicant]
Taiwanese Office Action for Application No. 104121758, dated Apr. 8, 2019, 7 pages. [English Translation].
[cited by applicant]
Takimoto et al., “Chronic Inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy”, Nat. Med., Feb. 2005, vol. 11, No. 2, pp. 214-222.
[cited by applicant]
Takimoto et al., “Compartmentalization of cardiac beta-adrenergic inotrophy modulation by phosphodiesterase type 5”, Circulation, Apr. 24, 2007, vol. 115, No. 16, pp. 2159-2167.
[cited by applicant]
Thacker et al., “Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation”, Ann. Thorac. Surg., Mar. 2010, vol. 89, No. 3, pp. 837-842.
[cited by applicant]
Trojnarska et al., “Challenges of management and therapy in patients with a functionally single ventricle after Fontan operation”, Cardiol. J., 2011, vol. 18, No. 2, pp. 119-127.
[cited by applicant]
“Trials will evaluate udenafil for heart defects in adolescents”, Healio Cardiology Today, Feb. 1, 2014, <http://www.healio.com.cardiology/pediatric-cardiology/news/online/%7Bda00eddc-5a3e-4a27-80d6-05b12bb3acc4%7D/tria…
[cited by applicant]
Tunisian Office Action for Application No. TN2017/0029 dated Sep. 27, 2017, [English Translation].
[cited by applicant]
Tunisian Office Action for Application No. TN2017/0029 dated Sep. 27, 2017. [Original].
[cited by applicant]
Tunks et al., “Sildenafil exposure and hemodynamic effect after Fontan surgery”, Pediatr. Crit. Care Med., Jan. 2014, vol. 15, No. 1, pp. 28-34.
[cited by applicant]
Ukranian Office Action mailed Jan. 16, 2018, for Ukranian Patent Application No. 2016 13574, 4 pages. [Original].
[cited by applicant]
Ukranian Office Action mailed Jan. 16, 2018, for Ukranian Patent Application No. 2016 13574, 4 pages. [English Translation].
[cited by applicant]
Ukrainian Notice of Decision to Grant for Patent Application No. a201613574, dated Feb. 15, 2019, 7 pages. [Original].
[cited by applicant]
Ukrainian Notice of Decision to Grant for Patent Application No. a201613574, dated Feb. 15, 2019, 13 pages. [English Translation].
[cited by applicant]
Uzun et al., “Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan”, Ann. Thrac. Surg., Dec. 2006, vol. 82, No. 6, e39-40.
[cited by applicant]
Van De Bruaene et al., “Sildenafil improves exercise hemodynamics in Fontan patients”., Circ. Cardiovasc Imaging, Mar. 2014, vol. 7, No. 2, pp. 265-273.
[cited by applicant]
Wasserman, E., “Mezzion Pharma Appoints Jefferson Gregory to Board of Directors”, Fierce Biotech, Oct. 9, 2014, <http://www.fiercebiotech.com/biotech/mezzion-pharma-appoints-jefferson-gregory-to-board-of-directors>.
[cited by applicant]
Written Opinion issued in related International Patent Application No. PCT/US2015/038638, dated Sep. 22, 2015.
[cited by applicant]
Zarin et al., “The ClinicalTrials.gov results database—update and key issues”, New England Journal of Medicine, Mar. 3, 2011, vol. 364, No. 9, pp. 52-60.
[cited by applicant]
Zhao et al., “Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial”, Eur. J. of Urology, vol. 60, (2…
[cited by applicant]
Zou et al., “Status and Analysis of New Drugs in the World”, First Edition, Press of the Second Military Medical University, Oct. 2010, p. 250. [Original].
[cited by applicant]
Zou et al., “Status and Analysis of New Drugs in the World”, First Edition, Press of the Second Military Medical University, Oct. 2010, p. 250. [English Translation].
[cited by applicant]